[Federal Register Volume 67, Number 166 (Tuesday, August 27, 2002)]
[Notices]
[Page 55026]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-21790]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel. N01-BC-27012-74: Early Phase Clinical Trial to Evaluate 
Safety and Immunogenicity of Human Papilomavirus VLP Base Vacines.
    Date: August 29, 2002.
    Time: 12 PM to 3 PM.
    Agenda: To review and evaluate contract proposals.
    Place: 6116 Executive Boulevard, 8th Floor, Bethesda, MD 20892, 
(Telephone Conference Call).
    Contact Person: Thomas M. Vollberg, PhD, Scientific Review 
Administrator, Special Review and Resources Branch, Division of 
Extramural Activities, National Cancer Institute, National Institute 
of Health, 6116 Executive Boulevard, Suite 703/7142, Rockville, MD 
20852, 301/594-9582, [email protected].
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: August 19, 2002.
Anna P. Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 02-21790 Filed 8-26-02; 8:45 am]
BILLING CODE 4140-01-M